Berthold F, Schultheis K H, Aigner K, Lampert F
Klin Padiatr. 1986 May-Jun;198(3):257-61. doi: 10.1055/s-2008-1026886.
A 33 months old girl and a 5 months old boy presented with unresectable hepatoblastoma (group III) and were treated with combination chemotherapy using Adriamycin, Cyclophosphamide, Cisplatinum (regimen I) and Adriamycin, Etoposide, Cisplatinum (regimen II). In both patients tumor size and alpha-fetoprotein levels decreased remarkably. Tumor regression was considerably enhanced by selective chemoembolization (Ethibloc, Adriamycin) of the right hepatic artery in one patient. After preoperative chemotherapy hepatoblastomas could be removed surgically. Local recurrence in the older patient was treated again successfully by surgery and chemotherapy. The patients are surviving disease-free 17 and 28 months from diagnosis. The efficacy of the treatment warrants prospective clinical trials in patients with unresectable hepatoblastoma.
一名33个月大的女孩和一名5个月大的男孩被诊断为无法切除的肝母细胞瘤(Ⅲ组),接受了使用阿霉素、环磷酰胺、顺铂(方案Ⅰ)以及阿霉素、依托泊苷、顺铂(方案Ⅱ)的联合化疗。两名患者的肿瘤大小和甲胎蛋白水平均显著下降。其中一名患者通过对右肝动脉进行选择性化疗栓塞(乙碘油、阿霉素),肿瘤消退明显增强。术前化疗后,肝母细胞瘤得以手术切除。年长患者的局部复发通过手术和化疗再次成功治疗。自诊断以来,两名患者分别无病存活了17个月和28个月。该治疗方法的疗效值得对无法切除的肝母细胞瘤患者进行前瞻性临床试验。